Featured Research

Latest Research


Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus
Infections in an Underserved Population


Rachel A. Stewart, DNP; Brooke R. MacDonald, MSPH; Tzu-Chun Chu, MS, MPH;
Jonathan D. Moore, MPH; Esther O. Fasanmi, PharmD; Rohit P. Ojha, DrPH


  • Why was this study conducted?
    • Underserved individuals (i.e. individuals with barriers to healthcare) have a high prevalence of hepatitis C virus (HCV) infections.
    • Many underserved individuals are ineligible for interferon-based HCV treatments.
    • New direct-acting antiviral regimens have made more people eligible for HCV treatment, but whether they work for underserved individuals is unknown, partly because underserved individuals are not well-represented in randomized controlled trials.
  • What did this study find?
    • In general, direct-acting antivirals are effective for treating underserved individuals with HCV infections.
    • Treatment with ledipasvir/sofosbuvir, in particular, resulted in nearly the same percentage of individuals cured as in randomized controlled trials.
  • What do the findings mean?
    • This study provides encouraging evidence for treating HCV infections for underserved individuals, which may be a way to reduce health disparities related to HCV infections.

Research Chart